Currentmedical mutual - ohioPolicy AHS - G2002 - Cervical Cancer Screening

Cervical Cancer Screening

Customize your policy alerts

Sign up for medical mutual - ohio Policy AHS - G2002 - Cervical Cancer Screening alerts

Get alerted when Policy AHS - G2002 - Cervical Cancer Screening changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Clinical coverage criteria for cervical cancer screening methods (Pap cytology, high-risk HPV testing, and co-testing) for individuals with a cervix, including special populations (immunocompromised, HIV, post-hysterectomy) and related limitations.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentmedical mutual - ohioPolicy AHS - G2002 - Cervical Cancer Screening

Cervical Cancer Screening

Customize your policy alerts

Sign up for medical mutual - ohio Policy AHS - G2002 - Cervical Cancer Screening alerts

Get alerted when Policy AHS - G2002 - Cervical Cancer Screening changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payermedical mutual - ohio

PolicyCervical Cancer Screening

Policy CodePolicy AHS - G2002 - Cervical Cancer Screening

Change TypePeriodic review (no material changes)

Effective DateFeb 1, 2026

Last ReviewDec 4, 2024

Next Review DateSep 4, 2025

Key ActionUse listed CPT/HCPCS procedure codes and approved FDA-cleared assays when submitting claims and perform reflex cytology from the same specimen for all positive primary HPV screening results.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

21-29ages 21–29: Pap q3y

30-65ages 30–65: Pap q3y or hr-HPV q5y or cotest q5y

Under 21screening not covered

Over 65routine screening not covered unless high-risk

3yreflex testing interval after negative hrHPV (min)

87623, multipleexample procedure codes listed

Coverage Criteria for Cervical Cancer Screening

inv-01: Covered Screening Scenarios

Covered when the specific age group and risk conditions below are met

Immunocompromised individuals: For immunocompromised or immunosuppressed individuals, any one of the following meets coverage: (a) annual cervical cytology testing for individuals of all ages; (b) co-testing (cervical cytology and high-risk HPV testing) once every 3 years for individuals 30 years of age or older.annual or q3y for co-testing

immunocompromised defined in ASCCP/section IV

General yearly Pap coverage: Yearly Pap screening by conventional or liquid-based Pap smear for individuals of all ages meets coverage criteria.annual

policy states yearly Pap meets coverage

Ages 21-29: Individuals 21–29: cervical cancer screening once every 3 years using conventional or liquid-based Pap smears meets coverage criteria.every 3 years

Pap preferred for this age group per guidance

Ages 30-65: Individuals 30–65: any one of the following meets coverage criteria: (a) conventional or liquid-based Pap smear once every 3 years; (b) high-risk HPV testing alone once every 5 years (primary hr-HPV); (c) co-testing (cytology with concurrent hr-HPV testing) once every 5 years.Pap q3y OR hr-HPV q5y OR cotest q5y

policy lists these three equivalent options

Pooled hr-HPV positive follow-up: For individuals who are pooled hr-HPV positive, nucleic acid testing (genotyping) for high-risk strains HPV16 and HPV18 meets coverage criteria.genotyping for 16/18

targeted genotyping after pooled positive

Younger/high-risk or prior abnormal follow-up: For individuals 65 years of age or younger, annual cervical cancer screening by Pap smear or hr-HPV testing meets coverage criteria when there is a prior abnormal cytology and/or prior positive HPV, or the individual is high-risk (eg, organ transplant, DES exposure).annual

applies to those with prior abnormal results or high-risk status

inv-02: Excluded / Not Covered Scenarios

Not covered when ANY of the following conditions apply

Age under 21: Cervical cancer screening (cervical cytology or high-risk HPV testing) for individuals less than 21 years of age does not meet coverage criteria.<21

applies to asymptomatic and immunocompetent individuals

Over 65 without risk: Routine cervical cancer screening for individuals over 65 years of age who are not immunocompromised, not immunosuppressed, and who are not considered high-risk (no prior abnormal cytology and no prior hr-HPV positive) does not meet coverage criteria.>65 and not high-risk

policy specifies exception for high-risk over 65

Post-hysterectomy: Cervical cancer screening for individuals who have undergone surgical removal of the uterus and cervix and who have no history of cervical cancer or precancer does not meet coverage criteria.

inv-03: Average-risk age-based screening

USPSTF / ACS screening recommendations for average-risk individuals (by age):

Women 21–29: Screen every 3 years with cytology (Pap) alone.q3y cytology

USPSTF Grade A; ACS notes Pap preferred for 21–29

Women 30–65: Screen every 3 years with cytology alone, or every 5 years with high-risk HPV testing alone, or every 5 years with co-testing (cytology plus hr-HPV).q3y cytology OR q5y hr-HPV or cotest

USPSTF Grade A; ACS aligns for preferred options

Younger than 21 or older than 65 with adequate prior screening or post-hysterectomy: Do not screen for cervical cancer (USPSTF recommends against screening in these scenarios).per USPSTF

inv-04: Risk-based management and testing

ASCCP risk-based management and testing recommendations:

Expedited treatment criteria: Expedited treatment without preceding colposcopic biopsy is preferred for nonpregnant patients ≥25 years when the immediate risk of CIN3+ is ≥60%; acceptable for risks between 25% and 60%; shared decision-making is recommended.CIN3+ >=60%

ASCCP 2019 guidance

Reflex triage testing for HPV-positive screens: When primary HPV screening is used, performance of an additional reflex triage test (eg, reflex cytology) for all positive HPV tests regardless of genotype is preferred; if HPV16/18 genotyping is positive and reflex testing from the same specimen is not feasible, referral for colposcopy and collection of an additional triage test at the colposcopy visit is acceptable.HPV positive

Ensures risk-based management and enables expedited treatment where appropriate

Self-collected sample management:

inv-05: Immunocompromised patient screening

Screening recommendations for non-HIV immunocompromised patients (ASCCP):

Solid organ transplant recipients: Cytology is recommended if younger than 30; co-testing is preferred if ≥30 (cytology acceptable if ≥30); if using cytology alone perform annual cytology until three consecutive normals then every 3 years; if using co-testing and both are normal, co-testing every 3 years; begin screening within 1 year of sexual debut if transplant before age 21; continue screening for life and discontinue based on shared decision regarding quality and duration of life rather than age.annual until 3 normals then q3y; lifelong screening

ASCCP Table 3 specifics

Allogeneic HSCT and GVHD: Cytology is recommended if younger than 30; co-testing is preferred if ≥30; if using cytology alone perform annual cytology until three consecutive normals then every 3 years; resume annual cytology with genital GVHD until three consecutive normals then every 3 years; continue lifetime screening and discontinue based on shared decision rather than age.annual until 3 normals then q3y; lifelong screening

Management varies with chronic or genital GVHD

inv-06: Guideline-based screening, triage, and surveillance criteria

Coverage and management follow guideline-based algorithms; examples extracted below represent conditions where testing, reflex triage, and surveillance are recommended:

Primary hrHPV screening age and interval: Primary hrHPV screening should not be initiated before age 25; rescreening after a negative primary hrHPV screen should occur no sooner than every 3 years; ASCO recommends HPV DNA testing every 5 years for ages 25–65 in maximal-resource settings.age >=25; interval >=3 or 5 years

Consolidates ASCCP/ASCO guidance

Reflex triage for positive HPV: All positive primary HPV screening tests should have additional reflex triage testing performed from the same laboratory specimen (eg, reflex cytology or genotyping for HPV16/18); if HPV16/18 positive, proceed to colposcopy even if cytology is negative.HPV positive

ACOG and CDC recommend reflex testing to inform colposcopy

Surveillance after treatment or high-risk results:

inv-07: FDA-approved assays and specimen types

Policy references FDA approvals and guidance relevant to primary HPV testing and specimen types:

FDA-cleared assays and specimen types: The COBAS HPV NAAT is FDA-approved for detection of 14 high-risk HPV types and specifically identifies HPV16 and HPV18; FDA approved expansion of COBAS use to SurePath preservative fluid and for Cobas 6800/8800 systems. The BD Onclarity HPV Assay is FDA-approved to detect 14 high-risk genotypes including HPV16 and HPV18 for cervical specimens collected in BD SurePath vial.FDA-approved assays/specimen types

Supports use of listed assays and specimen types for screening

Coverage criteria: Testing for cervical cancer does not meet coverage criteria in the following situations: screening of individuals younger than 21 years, routine screening of individuals over 65 years who are not immunocompromised, immunosuppressed, or otherwise high-risk (for example, no history of abnormal cytology or prior hr‑HPV positivity), and screening after surgical removal of the uterus and cervix when there is no history of cervical cancer or precancer. These exclusions are stated explicitly in the policy as scenarios that DOES NOT MEET COVERAGE CRITERIA.

Additional context: The policy revision history documents that the coverage rules were clarified to separate low‑risk HPV testing from other unapproved technologies; this same revision confirmed explicit denial language for screening outside recommended age and post‑hysterectomy contexts.

Cervical cancer screening is not useful for individuals who no longer have a cervix following a hysterectomy performed for a benign condition. The National Cancer Institute statement cited in the policy concludes: screening is not helpful in women without a cervix after hysterectomy for benign disease. Accordingly, routine cytology or hr‑HPV testing in this context does not meet coverage criteria unless there is a documented history of cervical cancer or precancer.

Testing that targets low‑risk HPV types (those typically associated with genital warts and not with progression to cervical cancer) is explicitly not indicated. The American Academy of Family Physicians' Choosing Wisely recommendation — quoted in the policy — advises: 'Don't perform low‑risk human papillomavirus (HPV) testing.' The policy therefore states that testing for low‑risk HPV DOES NOT MEET COVERAGE CRITERIA.

Revision history notes clarify the establishment of distinct coverage entries addressing low‑risk HPV testing and other unapproved technologies. The policy revision split the former combined criterion so that CC10 reads: 'Testing for low‑risk HPV DOES NOT MEET COVERAGE CRITERIA,' and the subsequent item addresses other technologies with insufficient evidence. This change is recorded in the policy revision summary.

The policy lists the full set of situations that DOES NOT MEET COVERAGE CRITERIA: screening individuals younger than 21 years; routine screening of individuals over 65 years who are not immunocompromised, immunosuppressed, or otherwise high‑risk (no prior abnormal cytology or prior hr‑HPV positivity); cervical cancer screening at any age for individuals who have undergone total hysterectomy (removal of uterus and cervix) with no history of cervical cancer or precancer; and testing for low‑risk HPV. The policy further states that all other technologies for cervical cancer screening not discussed in the document do not meet coverage criteria due to insufficient evidence.

The USPSTF recommendations summarized in the policy support the exclusions above. The USPSTF recommends against screening women younger than 21 and against routine screening of women older than 65 who have had adequate prior screening, and it recommends against screening women who have had a hysterectomy for benign disease. These guideline statements inform the policy's determination that such screening does not meet coverage criteria.

Although some organizations support primary high‑risk HPV (hrHPV) testing as an alternative screening strategy, the policy notes limitations for certain groups. ASCCP guidance cited in the policy indicates that primary hrHPV screening should not be initiated before age 25 and that rescreening after a negative primary hrHPV test should occur no sooner than every 3 years. The Department of Health and Human Services guidance referenced in the policy states that primary HPV testing is not recommended for certain groups (for example, specific recommendations apply to persons with HIV), and that HPV16 or 16/18 positivity should prompt referral to colposcopy.

Revision history documents that the policy explicitly designated low‑risk HPV testing as not meeting coverage criteria (CC10) and separated 'all other technologies not discussed above' into their own exclusion (now CC11/CC12), reflecting that low‑risk HPV testing has sufficient evidence to advise against its use and that other novel technologies lack adequate published evidence to support coverage.

Applicable Procedure and Billing Codes

Applicable CPT/HCPCS Procedure Codes (HPV NAAT and cytology)mixed

87623	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (e.g., 6, 11, 42, 43, 44).
87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result.
87625	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed.
87621	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (e.g., 16, 18, 31, 45, 51, 52) and high-risk pooled result(s).
88142	Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician.
88164	Cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision.
88167	Cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision.
88174	Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision.
88175	Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision.
88141	Cytopathology, slides, cervical or vaginal; manual screening under physician supervision.

Applicable CPT/HCPCS and Proprietary Codesmixed

87623	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (e.g., 6, 11, 42, 43, 44).
87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types, pooled result.
87625	Infectious agent detection by nucleic acid (DNA or RNA); HPV types 16 and 18 only, includes type 45, if performed.
87626	Infectious agent detection by nucleic acid (DNA or RNA); HPV separately reported high-risk types and pooled result(s).
88141-88167	Cytopathology, cervical or vaginal (various reporting systems and screening/rescreening modalities).
0502U	Proprietary test: QuantiVirusTM HPV E6/E7 mRNA Test for Cervical Cancer (DiaCarta, Inc).
G0123	Screening cytopathology, cervical or vaginal, collected in preservative fluid, requiring interpretation by physician.
G0124	Screening cytopathology smears, cervical or vaginal, performed by automated system, requiring physician interpretation.
G0141	Screening cytopathology smears by automated system with manual rescreening, requiring physician interpretation.
G0143	Screening cytopathology collected in preservative fluid with manual screening and rescreening by cytotechnologist under physician supervision.

1–10 of 18

1/2

Provider Actions, Billing, and Documentation

Prior Authorization

Prior authorization not required

No explicit prior authorization requirements are specified in this portion of the policy.

Step Therapy

Reflex cytology for all HPV-positive primary screens

Perform reflex cytology (from the same specimen) for all HPV-positive primary screening results; if reflex testing from the same laboratory specimen is not feasible, proceed directly to colposcopy and collect an additional triage specimen at that visit.

Reflex cytology is recommended because it enables expedited treatment decisions (e.g., HPV16-positive HSIL may qualify for treatment).
If same-specimen reflex testing cannot be done, obtain cytology at the colposcopy visit to inform risk-based management.

Background and Rationale

Cervical cancer screening is intended to detect precancerous lesions and early cancer using a combination of methods. The policy background summarizes that screening modalities include Papanicolaou (Pap) cytology, high‑risk HPV testing, and colposcopic evaluation as needed. It emphasizes the role of persistent infection with high‑risk HPV types — notably HPV‑16 and HPV‑18 — in the causal pathway to cervical intraepithelial neoplasia and cervical cancer, and it frames age‑ and risk‑based strategies (Pap, primary hrHPV, and cotesting) to identify and manage precancerous disease.

Definitions and Key Terms

inv-37: hr-HPV — High-risk human papillomavirus strains associated with cervical cancer (references types 16 and 18)

DefinitionHigh-risk human papillomavirus (hr-HPV): HPV genotypes associated with cervical cancer; the document specifically references types 16 and 18 as highest-risk.

Genotypes referencedPolicy and FDA-cleared assays detect 14 high-risk HPV types; assays can specifically identify HPV 16 and 18.

Clinical significancehr-HPV infection (particularly types 16/18) is the primary factor in development of cervical cancer and increases risk of CIN and invasive disease.

inv-38: Pap — Papanicolaou test (cervical cytology obtained by scraping ectocervix and endocervix).

DefinitionPap (Papanicolaou test): cervical cytology obtained by scraping the ectocervix and endocervix for cytologic evaluation.

Use

Document Revision History

2025-09-04reviewLatest

Reviewed and updated background, guidelines/recommendations, and evidence references; edited coverage criteria CC1, CC3, CC5, CC6, CC7, and CC8 for clarity and consistency; split CC10 into testing-for-low-risk-HPV (CC10) and other technologies (CC11) to state low-risk HPV testing does not meet coverage criteria.

2024-12-04coding update

Off-cycle coding modification: added CPT code 87626 (effective 2025-01-01), removed CPT code 0500T (deleted effective 2025-01-01), and revised code description for CPT 87624 (effective 2025-01-01).

Policy Summary

Payermedical mutual - ohio

PolicyCervical Cancer Screening

Policy CodePolicy AHS - G2002 - Cervical Cancer Screening

Change TypePeriodic review (no material changes)

Effective DateFeb 1, 2026

Last ReviewDec 4, 2024

Next Review DateSep 4, 2025

SourceLink

On This Page

post-total hysterectomy without history

Low-risk HPV testing: Testing for low-risk HPV types does not meet coverage criteria.low-risk HPV

explicitly denied

Other unsupported technologies: All other technologies for cervical cancer screening not discussed in this policy do not meet coverage criteria due to lack of sufficient published evidence.unspecified technologies

catch-all exclusion

Self-collected vaginal specimens may be acceptable for screening in asymptomatic, average-risk individuals; if self-collected HPV is negative, repeat in 3 years; if positive for HPV16/18, refer directly to colposcopy with concurrent cytology; for other hr-HPV positives, obtain clinician-collected specimen for cytology or dual stain per ASCCP recommendations.

ASCCP recommendations on self-sampling and follow-up

Other immunosuppressed conditions: For conditions such as inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis on immunosuppressants, follow general population screening guidelines but begin screening earlier if immunosuppressant therapy started before age 21 and continue lifelong screening with discontinuation decisions based on quality and duration of life rather than age.lifelong screening considerations

ASCCP provides condition-specific recommendations

Continued surveillance with HPV testing or co-testing at 3-year intervals for at least 25 years is recommended after treatment for HSIL, CIN2/3 or AIS; after treatment follow-up with HPV DNA testing at 12 months is recommended, and if positive continue annual screening.

ACOG and ASCO recommendations

HIV-specific recommendations: Women with HIV: age 21–29 should have Pap at baseline and annually, may extend to every 3 years after three normal Pap tests; age ≥30 options include annual Pap testing or baseline co-testing with 3-year interval if negative; HPV16/18 positivity warrants colposcopy.HIV infection

HHS and CDC guidance

Cytology-only use: Surveillance with cytology alone is acceptable only if HPV testing or co-testing is not feasible; cytology surveillance intervals are shorter (eg, 6–12 month intervals) compared to HPV-based surveillance.HPV testing not feasible

ACOG and CDC guidance

Billing Rule

Use listed CPT/HCPCS codes and approved assays

Use the procedure codes and FDA‑cleared/approved assays listed in the policy when submitting claims; verify payer lab policy requirements.

Examples of listed HPV NAAT and cytology codes include 87623–87626 and 88141–88167 (see policy code lists).
FDA‑approved assays (e.g., COBAS, BD Onclarity, APTIMA) and specified specimen types are referenced in the policy.

Billing Rule

Use applicable procedure/HCPCS codes and verify lab policy

Submit claims using the applicable procedure and HCPCS codes shown in the policy and follow payer laboratory policy for coding and billing requirements.

Policy lists applicable codes (e.g., 87623, 87624, 87625, 87626, 88141–88167, G0123–G0148, G0476, P3000–P3001, Q0091, 0502U).
Procedure codes in the policy are provided as a reference; always verify the most current version at the payer's lab policies site.

Step Therapy

No step therapy required

No step therapy requirements are specified in this portion of the policy.

Note

Expedited treatment thresholds (CIN3+ risk)

Expedited treatment (without preceding confirmatory biopsy) is preferred for nonpregnant patients ≥25 when the immediate risk of CIN3+ is ≥60%; it is acceptable when the immediate risk is 25–60% with shared decision‑making.

Expedited treatment is an option for HSIL cytology with HPV16 positivity and for never/rarely screened patients with HPV-positive HSIL cytology.
Expedited treatment requires cytology (hence the need for reflex cytology when primary HPV screening is used).

Billing Rule

Provider billing note — follow payer lab policy

Follow the billing note and payer lab policy guidance described in the policy when preparing claims for HPV and cytology testing.

Documentation Required

Verify member benefits and program-specific rules

Coverage determination depends on the individual's benefit coverage at the time of request; Medicare and Medicaid specifics are addressed in the 'Applicable State and Federal Regulations' section.

Verify member benefits and applicable government coverage (LCDs/NCDs/state Medicaid) prior to testing or submission.

Documentation Required

Document reflex testing or obtain triage specimen at colposcopy

If primary HPV screening is used and reflex triage testing from the same specimen is not feasible, proceed directly to colposcopy and collect an additional triage specimen at the colposcopy visit.

Collect cytology or other triage tests at colposcopy to inform risk‑based management.
Same‑specimen reflex testing is preferred to avoid repeat clinic visits.

Documentation Required

Require reflex testing from same specimen for HPV-positive results

Perform reflex cytology or other reflex triage testing from the same laboratory specimen for all positive primary HPV screening tests to inform management decisions.

Laboratories should perform reflex testing to avoid repeat clinic visits.
HPV16/18 positivity may require colposcopy even if cytology is negative; reflex testing helps identify these cases.

Note

Confirm procedure codes against payer lab policy

Procedure codes included in this policy are provided for reference; providers must verify the most current codes and coding guidance in the payer's laboratory policy.

The policy note states procedure codes are a general reference and may not be all‑inclusive.
Always confirm coding requirements at https://www.medmutual.com/LabPolicies.

Denial Risk

Do not screen individuals under age 21

Cervical cytology or hr‑HPV screening for individuals under 21 years of age will be denied (DOES NOT MEET COVERAGE CRITERIA).

This exclusion applies to screening in asymptomatic, immunocompetent individuals younger than 21.

Denial Risk

Routine screening outside >65 without risk will be denied

Routine cervical cancer screening for individuals over 65 years who are not immunocompromised, not high‑risk, and who have had adequate prior screening will be denied (DOES NOT MEET COVERAGE CRITERIA).

Continue screening for over‑65 individuals only if they are immunocompromised or have prior abnormal cytology/hr‑HPV positive history.

Denial Risk

Do not screen post‑total hysterectomy without prior disease

Cervical cancer screening after total hysterectomy (removal of uterus and cervix) in individuals with no history of cervical cancer or precancer will be denied (DOES NOT MEET COVERAGE CRITERIA).

Screening is not indicated for persons without a cervix following benign hysterectomy.

Denial Risk

Do not perform low‑risk HPV testing

Testing for low‑risk HPV types does not meet coverage criteria and will be denied.

Policy explicitly states testing for low‑risk HPV DOES NOT MEET COVERAGE CRITERIA.

Denial Risk

Avoid screening outside recommended age groups

Screening outside recommended age groups or without an adequate indication (e.g., routine screening >65 with adequate prior screening) may be denied per policy and guideline recommendations.

Follow USPSTF age‑based recommendations (do not screen <21 or >65 with adequate prior screening).

Denial Risk

Follow government policy when it conflicts with this policy

If this policy conflicts with applicable government policies (e.g., LCDs, NCDs, or state Medicaid rules), the government policy takes precedence and failure to follow it may result in denial.

Verify Medicare and Medicaid coverage rules via the CMS coverage database or applicable state Medicaid website before testing.

Billing Rule

G0476 requires concurrent Pap — verify coverage implications

When billing HPV screening with HCPCS G0476 note that the policy describes G0476 as 'for cervical cancer screening, must be performed in addition to pap test' — lack of a concurrent Pap test could affect coverage or payment.

G0476 is specified as 'must be performed in addition to pap test' for cervical cancer screening per the policy code list.
Ensure documentation supports any claim using G0476 and concurrent Pap testing where applicable.

Recommended every 3 years for persons aged 21–29; part of screening options for ages 30–65 (Pap alone q3y or cotesting q5y).

Role in reflex testingCytology may be performed as a reflex/triage test for positive HPV results to determine next management steps, including colposcopy.

inv-39: Cotesting — Screening using both Pap cytology and HPV DNA testing simultaneously; more sensitive for detecting abnormalities in women ≥30

DefinitionCotesting: simultaneous screening with both Pap cytology and HPV DNA testing performed together on the same individual specimen.

PerformanceCotesting in women ≥30 is more sensitive for detecting cervical abnormalities than Pap alone but associated with more false positives and downstream procedures.

Recommended intervalWhen used for average-risk persons aged 30–65, cotesting is recommended every 5 years as one acceptable screening strategy.

inv-40: Self-collected vaginal specimen — Patient-collected vaginal sample for HPV testing acceptable for screening in asymptomatic, average-risk individuals with a cervix; clinic-collected preferred if concerns

DefinitionSelf-collected vaginal specimen: a patient-collected vaginal sample used for HPV testing in asymptomatic, average-risk individuals with a cervix.

AcceptabilitySelf-collection is acceptable for screening in asymptomatic, average-risk people, but clinician-collected cervical specimens remain preferred.

Management implicationsIf self-collected specimen is HPV-negative, repeat testing in 3 years; if HPV16/18 positive, direct referral to colposcopy with concurrent cytology collection is recommended.

inv-41: Primary hrHPV testing — Screening that tests for high-risk HPV types as the initial test instead of cytology; recommended as an alternative to cytology/co-testing for some age groups

DefinitionPrimary hrHPV testing: using an assay that detects high-risk HPV types as the initial screening test instead of cytology.

Age and initiationPrimary hrHPV screening should not be initiated before age 25; guidance supports its use as an alternative to cytology-based screening.

Rescreening intervalAfter a negative primary hrHPV test, rescreening should occur no sooner than every 3 years; some organizations (ASCO/CDC) endorse a 5-year interval for HPV-alone screening in ages 30–65.

inv-42: Reflex cytology/triage testing — Additional cytology or genotyping performed from the same specimen when primary HPV is positive to determine need for colposcopy or further evaluation

DefinitionReflex cytology/triage testing: additional cytology or genotyping performed from the same specimen when a primary HPV test is positive to determine need for colposcopy or further evaluation.

Operational noteAll positive primary HPV screening tests should have reflex triage testing performed from the same laboratory specimen; if not feasible, proceed to colposcopy and collect a triage specimen at that visit.

Implication of HPV16/18HPV 16 or 18 positivity warrants additional evaluation and may prompt colposcopy even if cytology is negative.

inv-43: NAAT — Nucleic acid amplification test detecting 14 high-risk HPV genotypes; some assays identify HPV 16 and 18 specifically.

DefinitionNAAT (Nucleic Acid Amplification Test) for HPV: molecular assays that detect viral nucleic acid and are used to identify high-risk HPV genotypes.

Scope of detectionFDA-cleared NAATs (eg, COBAS, BD Onclarity) detect 14 high-risk HPV genotypes and can specifically identify HPV types 16 and 18.

Use in screeningNAATs are the platform for primary hrHPV screening and are used in FDA-approved assays for first-line cervical cancer screening when validated for the specimen type.